News

Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumor histopathology images.

The company’s published study shows that its AI-powered Enlight-DP platform can predict cancer treatment response from histopathology slides.

Pangea Biomed, the company behind the world’s most advanced cancer response predictor, ENLIGHT, today announced that new findings establishing the efficacy of its novel ENLIGHT-DP platform have been published in Nature Cancer. The study, conducted in collaboration with researchers from the Australian National University and from the US National Cancer Institute, reveals that combining ENLIGHT with the DeepPT approach for inferring gene expression from H&E slide scans significantly advanced the ability to predict therapeutic responses across multiple cancer types and drugs from histopathology images.  

Dr. Amar Drawid sat down with Tuvik Beker to discuss the evolution of precision medicine, the challenges in matching the right drugs to the right patient, and how Pangea uses AI to analyze expression data and gene interaction maps to select the most effective drugs for individual patients.

Brian Gormley talked with Tuvik Beker and other AI and oncology experts about how startups are using AI to accurately diagnose and treat cancer patients.

Pangea announces its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.

Pangea will conduct ENLIGHT analyses for FibroFighters’ patients to suggest treatment avenues, compare recommended treatments to actual outcomes, and improve models for response prediction

The Sunday Times’ tech correspondent Danny Fortson brings on Ranit Aharonov to talk about this moment for artificial intelligence, studying the brain, Project Debater, neural networks, language’s AlphaGo moment, the big idea at Pangea, getting it into the hands of doctors and drug communities, the role of AI in this tool, the regulatory limits, and why she didn't debate the AI she created.

Karen Jagoda brings on Tuvik Beker and Ranit Aharonov to talk about precision oncology and the understanding of gene interactions and vulnerability of tumors.

glBRCA pancreatic ductal adenocarcinoma (PDAC) has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. In this study, we aimed to recapitulate the glBRCA PDAC population spectrum of responses to platinum and PARPi therapy, to explore the genomic and clinical features that may lead to different responses, and to investigate the mechanisms of resistance.